OptimizerRx outlines $118M-$124M 2026 revenue target amid early contract visibility and digital pharma momentum
Source: SeekingAlpha
2025-11-07 05:56:52 ET
More on OptimizeRx
- OptimizeRx Corporation (OPRX) Q3 2025 Earnings Call Transcript
- OptimizeRx: How It Is Changing Pharma Marketing
- OptimizeRx Non-GAAP EPS of $0.20 beats by $0.15, revenue of $26.1M beats by $2.41M
- OptimizeRx Q3 2025 Earnings Preview
- Seeking Alpha’s Quant Rating on OptimizeRx
Read the full article on Seeking Alpha
For further details see:
OptimizerRx outlines $118M–$124M 2026 revenue target amid early contract visibility and digital pharma momentum
OptimizeRx Corporation
NASDAQ: OPRX
OPRX Trading
0.65% G/L:
$6.15 Last:
311,923 Volume:
$6.01 Open:
OPRX Latest News
March 05, 2026 05:04:30 pm
UPDATE - OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
March 05, 2026 04:01:00 pm
OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
OPRX Stock Data
$189,855,041
17,596,775
3.29%
31
N/A
Healthcare Providers & Services
Healthcare
US
Waltham
